# Youn H. Kim

Source: https://onco.cc/people/youn-kim/  
OnCo record `youn-kim` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Stanford dermatologist who led MAVORIC, the trial that established mogamulizumab for mycosis fungoides and Sézary syndrome after earlier treatment.

## Summary

Youn Kim directs the cutaneous lymphoma programme at Stanford. She was first author of the 2018 Lancet Oncology report of MAVORIC, the phase 3 trial in which the anti-CCR4 antibody mogamulizumab improved progression-free survival compared with vorinostat in previously treated mycosis fungoides and Sézary syndrome, the basis for its approval. She has led many trials of new agents in cutaneous T-cell lymphoma and helped define its staging and response criteria.

## Fields

- Kind: Person
- Last checked: 2026-09-18
- Tags: lymphoma; dermatology; trialist
- Role: Dermatologist and Director of the Multidisciplinary Cutaneous Lymphoma Program, Stanford
- Specialisms: Cutaneous T-cell lymphoma; Mycosis fungoides and Sézary syndrome; Novel therapies

## Connected records

- cancers: [Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome)](https://onco.cc/cancers/cutaneous-t-cell-lymphoma/), [Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)](https://onco.cc/cancers/peripheral-t-cell-lymphoma/)
- institutions: [Stanford Health Care / Stanford Cancer Institute](https://onco.cc/institutions/stanford/)
- trials: [MAVORIC](https://onco.cc/trials/mavoric/)
- key papers: [MAVORIC: mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma](https://onco.cc/key-papers/paper-mavoric-mogamulizumab-lancet-oncol-2018/)

---
JSON: https://onco.cc/api/v1/entities/youn-kim.json